Apr, 05 2019 10:45 JST

Source: Eisai

Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug

Motion Sickness Solution Now Available in Convenience Stores

TOKYO, Apr, 05 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday, April 8.

Travelmin Support is a quasi-drug that contains plant derived daylily extract as its main ingredient to help with motion sickness and discomfort. As a drop-type product, it is easy for children to take, and it has a refreshing cider flavor. Each drop is individually wrapped for convenience, is easy to carry around, and can be taken by both adults and children five of age and older.

After hearing the voices of many consumers who had difficulties because they forgot to purchase motion sickness medicine and were unable to obtain any during their travels, Eisai decided to launch Travelmin Support as a quasi-drug that can be purchased even at convenience stores and others.

The Travelmin series is widely familiar in Japan as a national brand of motion sickness medicines. In addition to Travelmin, which was introduced in 1952, Eisai has launched the drop-type product Travelmin Churop (class 2 pharmaceutical product) which can be taken even after becoming sick, Travelmin R (class 2 pharmaceutical product) which contains ingredients that comparatively cause less sleepiness, and others. With the introduction of Travelmin Support to the Travelmin lineup, Eisai will continue to contribute to people concerned about motion sickness and discomfort when traveling, as well as help consumers enjoy their travels.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: HealthCare

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
April 08 2019 13:06 JST
 
Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
April 08 2019 10:43 JST
 
Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
March 29 2019 10:46 JST
 
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
March 22 2019 10:37 JST
 
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
March 22 2019 10:23 JST
 
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
March 21 2019 23:25 JST
 
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
March 12 2019 07:43 JST
 
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
March 07 2019 11:30 JST
 
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
February 27 2019 10:52 JST
 
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
February 21 2019 13:50 JST
 
More Press release >>

Latest Press Release


More Latest Release >>